Home/Top Cited Articles

Top Cited Articles

Acceptance rate:
21%
Time to first decision with review:
45 days*
Acceptance to publication:
27 days*
2023 total content views:
28516
How we get these metrics
*median number of days
Global trends in incidence, death, burden and risk factors of early-onset cancer from 1990 to 2019 Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study The English National Lynch Syndrome transformation project: an NHS Genomic Medicine Service Alliance (GMSA) programme Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps Use of immunosuppression and subsequent cancer incidence: cohort study Long-term opioid therapy trajectories and overdose in patients with and without cancer. COVID-19 and cancer in the UK: which will prove to be the lesser of two evils? Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunities Evidence-based practice in oncology, when it suits us?
Modern cancer trials still lack information about QoL impacts on patients Novel proteomics-based plasma test for early detection of multiple cancers in the general population Sex and authorship in global cancer research Globalisation of clinical trials in oncology: a double-edged sword? Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath Exploring the value of routinely collected data on EQ-5D-5L and other electronic patient-reported outcome measures as prognostic factors in adults with advanced non-small cell lung cancer receiving immunotherapy Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ views ‘Godrevy Project’: virtual reality for symptom control and well-being in oncology and palliative care – a non-randomised pre-post interventional trial Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy